GeneProtT, Inc. and Waters Corporation (NYSE:WAT) today announced the
formation of a technology partnership that will result in an expansion of
the proteomics capabilities that GeneProt plans to offer to the
pharmaceutical industry through its new industrial-scale proteomics facility
in the United States. Waters, through its wholly-owned subsidiary, Micromass
U.K. Ltd., will purchase equity securities of GeneProt with a maximum value
of US$10 million. At the same time, GeneProt will purchase approximately
US$20 million of mass spectrometry equipment, related systems and services
from Micromass.
For full press release visit www.micromass.co.uk and follow the link on the
homepage.
Steve Smith
Micromass UK
